Search
Menu
DataRay Inc. - ISO 11146-Compliant Laser Beam Profilers

Thermo Fisher Closes Phadia Deal

Facebook X LinkedIn Email
Thermo Fisher Scientific Inc. has completed the acquisition of Phadia of Uppsala, Sweden, a provider of blood tests for the clinical diagnosis and monitoring of allergies and autoimmune diseases.

Phadia now is part of Thermo Fisher’s Specialty Diagnostics business. The company is expected to contribute $0.07 to Thermo Fisher’s 2011 full-year adjusted earnings per share (EPS), an increase of $0.01 over the original estimate. Because of the favorable financing rates for the fourth quarter, the US company has adjusted its full-year EPS, which could result in a 20% to 23% EPS growth over 2010, it said.

In addition, Phadia is expected to add $190 million to the company’s 2011 revenue results, about a 12% growth in revenue over 2010.

For more information, visit: www.thermofisher.com  
Meadowlark Optics - Building system MR 7/23

Published: August 2011
AmericasBiophotonicsblood test monitoringblood tests for clinical diagnosisBusinessearnings per shareEPSEuropeMassachusettsPhadiaSwedentesting for allergies and autoimmune diseasesThermo FisherThermo Fisher ScientificThermo Fisher Specialty Diagnostics

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.